To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Raptiva

The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 11-0 that the overall risk-benefit comparison for psoriasis compound

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE